10 Geographic Atrophy Clinical Trials in Fairfax, VA (2026)

Q: How do I join a clinical trial in Fairfax?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Fairfax research site will contact you.

Recruiting Geographic Atrophy Studies in Fairfax

NCT04379596Recruiting

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemoth...

Fairfax, VAPHASE2450 participantsAstraZeneca

View Study Details

NCT05482893Recruiting

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and prelimi...

Fairfax, VAPHASE1258 participantsPhanes Therapeutics

View Study Details

NCT05683418Recruiting

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

The goal of this clinical trial is to evaluate the safety and efficacy of TOS-358 in women with HR+ HER2- metastatic breast cancer whose tumors have a mutation in PIK3CA and who meet all other study e...

Fairfax, VAPHASE1241 participantsTotus Medicines

View Study Details

NCT06022029Recruiting

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expan...

Fairfax, VAPHASE1168 participantsOncoNano Medicine, Inc.

View Study Details

NCT07529808Recruiting

Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma

This study is looking at how safe BHB810 is in adults with gastric and gastroesophageal adenocarcinoma (GEJ). The purpose of this study is also to look at: how well the study drug works, how the study...

Fairfax, VAPHASE1164 participantsBigHat Biosciences, Inc.

View Study Details

NCT06999187Recruiting

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refra...

Fairfax, VAPHASE196 participantsDren Bio

View Study Details

NCT05957367Recruiting

A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of inlexisertib in combination with anticancer therapies. Modules within the master pro...

Fairfax, VAPHASE194 participantsDeciphera Pharmaceuticals, LLC

View Study Details

NCT07082543Recruiting

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis

An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of GM1 gan...

Fairfax, VAPHASE375 participantsAzafaros A.G.

View Study Details

NCT06805825Recruiting

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit....

Fairfax, VAPHASE167 participantsNovelty Nobility, Inc.

View Study Details

NCT05487599Recruiting

A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)

Study J3Z-MC-OJAE is a Phase 1/2, multicenter, open-label, dose-finding study of LY3884961 evaluating the safety and tolerability in adults with peripheral manifestations of GD. Up to 3 dose levels o...

Fairfax, VAPHASE115 participantsPrevail Therapeutics

View Study Details

About Geographic Atrophy Clinical Trials in Fairfax

Geographic atrophy is the advanced form of dry age-related macular degeneration, involving progressive loss of retinal cells. It leads to enlarging blind spots in central vision. Recently approved complement inhibitor therapies can slow progression.

There are currently 10 geographic atrophy clinical trials recruiting participants in Fairfax, VA. These studies are seeking a combined 1,628 participants. Research is being sponsored by AstraZeneca, Phanes Therapeutics, Totus Medicines and 7 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Geographic Atrophy Clinical Trials in Fairfax — FAQ

Are there geographic atrophy clinical trials in Fairfax?

Yes, there are 10 geographic atrophy clinical trials currently recruiting in Fairfax, VA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Fairfax?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Fairfax research site will contact you about next steps.

Are clinical trials in Fairfax free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Fairfax studies also compensate for your time and travel.

What geographic atrophy treatments are being tested?

The 10 active trials in Fairfax are testing new therapies including novel drugs, biologics, and treatment approaches for geographic atrophy.

Data updated July 19, 2026 from ClinicalTrials.gov